View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 8, 2020

Smith+Nephew to launch revision total hip arthroplasty system in China

UK-based medical technology company Smith+Nephew has obtained approval from National Medical Products Administration (NMPA) to launch its REDAPT System for revision total hip arthroplasty (rTHA) in China.

UK-based medical technology company Smith+Nephew has obtained approval from National Medical Products Administration (NMPA) to launch its REDAPT System for revision total hip arthroplasty (rTHA) in China.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The REDAPT System is designed to help surgeons to overcome the challenges of revision hip arthroplasty, including the fixation in various bone types, the achievement of joint stability, predictable stem position and surgical efficiency.

It helps to lower the re-revision rate of rTHAs by reducing the frequency of implant movement, which is considered a major cause for early failure of total hip arthroplasty.

Furthermore, the REDAPT System has acetabular components that are among the first 3D-printed, imported, acetabular products approved for use in China.

Smith+Nephew Greater China managing director Ala Ahram said: “China has seen rapid growth in primary hip procedures over the past 15-20 years and as such, there is a need for technologies addressing the clinical needs for revision hip arthroplasty.

“Introducing the REDAPT System in China will have a profoundly positive clinical impact to our surgeon customers.”

Revision total hip arthroplasty procedure volume is expected to increase globally as younger, more active patients outlive their original implants.

The approval of REDAPT System expands Smith+Nephew’s portfolio of both primary and revision hip arthroplasty products currently available in China. The system is expected to be commercially available in China later this year.

In July, Smith+Nephew launched a handheld robotics platform for unicompartmental knee arthroplasty and total knee arthroplasty.

In January, the company acquired Tusker Medical for an undisclosed amount as part of its strategy to invest in advanced technologies to meet medical requirements.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network